Patents by Inventor Christopher M. Liu

Christopher M. Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibiting the transient receptor potential A1 ion channel
    Patent number: 10428072
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: October 1, 2019
    Assignee: Eli Lilly and Company
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher M. Liu, Guohua Liang, Matthew F. Baevsky, Richard A. Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans
  • INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL
    Publication number: 20180230149
    Abstract: The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).
    Type: Application
    Filed: March 29, 2018
    Publication date: August 16, 2018
    Inventors: Blaise S. Lippa, Xinyuan Wu, Qingyi Li, Iwona Wrona, Andrew J. Jackson, Bertrand L. Chenard, Christopher M. Liu, Guohua Liang, Matthew F. Baevsky, Richard A. Earl, Lisa Mcqueen, Jared Smit, Brett A. Cowans
  • Inhibiting the transient receptor potential A1 ion channel
    Patent number: 9394308
    Abstract: This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: July 19, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Qingyi Li, Lily Cheng, Christopher M. Liu, Iwona E. Wrona, Blaise S. Lippa, Chester A. Metcalf, III, Andrew J. Jackson, Lauren M. Chapman
  • Antibiotic compositions for the treatment of gram negative infections
    Patent number: 8906866
    Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 9, 2014
    Assignees: BioSource Pharm, Inc., Cubist Pharmaceuticals, Inc.
    Inventors: William V. Curran, Christopher M. Liu, Amy C. D. Bombardier, Richard A. Leese, You Seok Hwang, Blaise S. Lippa, Yanzhi Zhang
  • INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL
    Publication number: 20140206650
    Abstract: This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 24, 2014
    Inventors: Blaise S. Lippa, Qingyi Li, Lily Cheng, Christopher M. Liu, Iwona E. Wrona, Chester A. Metcalf, III, Andrew J. Jackson
  • Antibiotic compositions for the treatment of gram negative infections
    Patent number: 8415307
    Abstract: Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: April 9, 2013
    Assignees: BioSource Pharm, Inc., Cubist Pharmaceuticals, Inc.
    Inventors: William V. Curran, Christopher M. Liu, Amy C. D. Bombardier, Richard A. Leese, You Seok Hwang, Blaise S. Lippa, Yanzhi Zhang